These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 23047236)
1. Ipilimumab for advanced melanoma: a pharmacologic perspective. Trinh VA; Hagen B J Oncol Pharm Pract; 2013 Sep; 19(3):195-201. PubMed ID: 23047236 [TBL] [Abstract][Full Text] [Related]
2. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Graziani G; Tentori L; Navarra P Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211 [TBL] [Abstract][Full Text] [Related]
3. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Lipson EJ; Drake CG Clin Cancer Res; 2011 Nov; 17(22):6958-62. PubMed ID: 21900389 [TBL] [Abstract][Full Text] [Related]
4. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069 [TBL] [Abstract][Full Text] [Related]
5. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Camacho LH Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884 [TBL] [Abstract][Full Text] [Related]
7. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Weber JS; Dummer R; de Pril V; Lebbé C; Hodi FS; Cancer; 2013 May; 119(9):1675-82. PubMed ID: 23400564 [TBL] [Abstract][Full Text] [Related]
8. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Patel SP; Woodman SE Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918 [TBL] [Abstract][Full Text] [Related]
9. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Wolchok JD; Hodi FS; Weber JS; Allison JP; Urba WJ; Robert C; O'Day SJ; Hoos A; Humphrey R; Berman DM; Lonberg N; Korman AJ Ann N Y Acad Sci; 2013 Jul; 1291(1):1-13. PubMed ID: 23772560 [TBL] [Abstract][Full Text] [Related]
10. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319 [TBL] [Abstract][Full Text] [Related]
11. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151 [TBL] [Abstract][Full Text] [Related]
12. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Hersh EM; O'Day SJ; Powderly J; Khan KD; Pavlick AC; Cranmer LD; Samlowski WE; Nichol GM; Yellin MJ; Weber JS Invest New Drugs; 2011 Jun; 29(3):489-98. PubMed ID: 20082117 [TBL] [Abstract][Full Text] [Related]
13. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Boasberg P; Hamid O; O'Day S Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058 [TBL] [Abstract][Full Text] [Related]
14. Ipilimumab in patients with cancer and the management of dermatologic adverse events. Lacouture ME; Wolchok JD; Yosipovitch G; Kähler KC; Busam KJ; Hauschild A J Am Acad Dermatol; 2014 Jul; 71(1):161-9. PubMed ID: 24767731 [TBL] [Abstract][Full Text] [Related]
15. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424 [TBL] [Abstract][Full Text] [Related]
17. Ipilimumab: in previously treated patients with advanced melanoma. Sanford M BioDrugs; 2012 Jun; 26(3):185-93. PubMed ID: 22530681 [TBL] [Abstract][Full Text] [Related]